 |
| Greg Nash-Pool/Getty Images |
'Is anyone surprised that the public is now hesitant to believe ANY CDC recommendations?,' Paul asks
The Centers for Disease Control and Prevention's (CDC's) 2024-2025 COVID-19 vaccine immunization schedule advises, in the case of the 2024-2025 Pfizer-BioNTech vaccine, three doses for children ages 6 months old through 4 years old — and Sen. Rand Paul has suggested that such guidance is leading to public hesitancy to trust the agency's recommendations.
"Pfizer drug reps…Uh, I mean, the Biden/Harris CDC, insists your 6-month-old get 3 COVID vaccines despite no scientific studies demonstrating decreased hospitalization or death. Is anyone surprised that the public is now hesitant to believe ANY CDC recommendations?" the lawmaker posted.
Regarding the 2024-2025 Pfizer-BioNTech COVID-19 vaccine, the CDC's vaccine schedule suggests previously unvaccinated children in the 6-month through 4-year-old age bracket should receive an initial dose, followed by another "at least 3–8 weeks after Dose 1," and a third "at least 8 weeks after Dose 2."
"An 8-week interval between the first and second doses of Pfizer-BioNTech COVID-19 Vaccine might be optimal for some people, as it might reduce the rare risk of myocarditis and pericarditis associated with COVID-19 vaccines," the CDC notes.
Paul, who tested positive for COVID-19 in 2020, noted in 2021 that he had not been vaccinated. --->READ MORE HERE
 |
| EvgeniyShokole / iStock |
The Centers for Disease Control and Prevention (CDC) vaccine advisory group today recommended a second 2024-25 COVID-19 vaccine dose, spaced 6 months apart, for people ages 65 and older and for people in younger age-groups who have moderate or severe immunocompromising conditions.
The group also recommended an extra dose, three or more, in people with immunocompromising conditions, based on shared decision-making between patient and doctor.
The recommendation replaces a vaguer "additional doses" wording that the Advisory Committee on Immunization Practices (ACIP) used in its advice over the summer for at-risk groups for the 2024-25 vaccines. The group made the change to simplify and standardize language used for its routine immunization schedules.
The three-part vote passed unanimously.
Challenges in maintaining protection
The ACIP work group that proposed the recommendation grappled with several factors, including a lack of seasonality of SARS-CoV-2 circulation, the epidemiology of the disease, waning vaccine effectiveness, and variant changes.
Vaccine timing has become complex, especially given tough-to-predict waves involving new COVID variants that sometimes spike in warm-weather months, after protection from vaccination in the fall months has waned, but before updated vaccines arrive on the market. For example, over the past spring and summer, COVID activity circulated at a high level over many months. --->READ MORE HEREFollow links below to relevant/related stories and resources:
Studies show long-COVID symptoms distinct from other respiratory infections, common in Marines
Vaccines for flu and COVID: Should you get both at the same time?
USA TODAY: Coronavirus Updates
WSJ: Coronavirus Live Updates
YAHOO NEWS: Coronavirus Live Updates
NEW YORK POST: Coronavirus The Latest
If you like what you see, please "Like" and/or Follow us on FACEBOOK here, GETTR here, and TWITTER here.
No comments:
Post a Comment